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Background: Binding of adhesive proteins (i.e., ﬁbrinogen, ﬁbronectin, vitronectin) to platelet integrin
glycoprotein IIb/IIIa (aIIb/b3) by various agonists (thrombin, collagen, adenosine diphosphate) involve in
strength of thrombus. This study was carried out to evaluate the antiplatelet effect of total saponin from
Korean Red Ginseng (KRG-TS) by investigating whether KRG-TS inhibits thrombin-induced binding of
ﬁbrinogen and ﬁbronectin to aIIb/b3.
Methods: We investigated the effect of KRG-TS on phosphorylation of vasodilator-stimulated phospho-
protein (VASP) and dephosphorylation of phosphatidylinositol 3-kinase (PI3K) and Akt, affecting binding
of ﬁbrinogen and ﬁbronectin to aIIb/b3, and clot retraction.
Results: KRG-TS had an antiplatelet effect by inhibiting the binding of ﬁbrinogen and ﬁbronectin to aIIb/
b3 via phosphorylation of VASP (Ser157), and dephosphorylation of PI3K and Akt on thrombin-induced
platelet aggregation. Moreover, A-kinase inhibitor Rp-8-Br-cyclic adenosine monophosphates (cAMPs)
reduced KRG-TS-increased VASP (Ser157) phosphorylation, and increased KRG-TS-inhibited ﬁbrinogen-,
and ﬁbronectin-binding to aIIb/b3. These ﬁndings indicate that KRG-TS interferes with the binding of
ﬁbrinogen and ﬁbronectin to aIIb/b3 via cAMP-dependent phosphorylation of VASP (Ser157). In addition,
KRG-TS decreased the rate of clot retraction, reﬂecting inhibition of aIIb/b3 activation. In this study, we
clariﬁed ginsenoside Ro (G-Ro) in KRG-TS inhibited thrombin-induced platelet aggregation via both
inhibition of [Ca2þ]i mobilization and increase of cAMP production.
Conclusion: These results strongly indicate that KRG-TS is a beneﬁcial herbal substance inhibiting
ﬁbrinogen-, and ﬁbronectin-binding to aIIb/b3, and clot retraction, and may prevent platelet aIIb/b3-
mediated thrombotic disease. In addition, we demonstrate that G-Ro is a novel compound with anti-
platelet characteristics of KRG-TS.
Copyright  2015, The Korean Society of Ginseng, Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Platelet aggregation is caused by “inside-out signaling” and
“outside-in signaling”, which is absolutely essential for the for-
mation of a hemostatic plugwhen normal blood vessels are injured.Laboratory Science, College of Bio
rk.
ht  2015, The Korean Society of G
c-nd/4.0/).However, platelet aggregation can also cause circulatory disorders,
such as thrombosis, atherosclerosis, and myocardial infarction [1].
Various agonists [i.e., collagen, thrombin, adenosine diphos-
phate (ADP)] induce “inside-out signaling” to bind adhesive pro-
teins (i.e., ﬁbrinogen, ﬁbronectin, vitronectin) to glycoprotein IIb/medical Science and Engineering, Inje University, 197, Inje-ro, Gimhae, Gyungnam
inseng, Published by Elsevier Ltd. This is an open access article under the CC BY-NC-
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signaling” is subsequently processed to cause a series of signal
events (i.e., Ca2þ mobilization, granule secretion, clot retraction)
[2e4]. Through these signaling events, intravascular platelets
ﬁnally are aggregated at the site of vascular wall injury, which
contributes to intensity of the formation of thrombus.
Vasodilator-stimulated phosphoprotein (VASP) phosphoryla-
tion inhibits VASP afﬁnity for contractile protein ﬁlamentous actin,
and ﬁbrinogen binding to aIIb/b3 to inhibit the ﬁnal common
pathway for platelet aggregation [5,6]. On the contrary, phospha-
tidylinositol 3-kinase (PI3K)/Akt phosphorylation involves aIIb/b3
activation [7]. Therefore, the upregulation of VASP phosphorylation
and the downregulation of PI3K/Akt phosphorylation are para-
mount important indexes to understand aIIb/b3 activation, and are
very useful for evaluating the antiplatelet effect of substances or
compounds. For instance, a major catechin analogue, (-)-epi-
gallocatechin-3-gallate from green tea, and caffeic acid are known
to produce cAMP via adenylate cyclase activation and subsequently
phosphorylates VASP (Ser157) to inhibit [Ca2þ]i mobilization [8,9].
In addition, abciximab, etiﬁbatide, tiroﬁban, and lamiﬁban are
known as aIIb/b3 antagonists [10,11].
Ginseng, the root of Panax ginseng Meyer, has been used
frequently in traditional Oriental medicine, and is known to have
various pharmacological activities such as anti-inﬂammatory ac-
tion, antioxidation, antitumor, antidiabetes, and antihepatotoxicity
effects [12,13]. It was recently reported that Korean Red Ginseng has
an effect on cardiovascular disease, which is characterized with
regard to reduction of blood pressure and arterial stiffness by inhi-
bition of Rho kinase [14], anticoagulation byprolongedprothrombin
and activated partial thromboplastin time [15], endothelium
relaxation by nitric oxide-cyclic guanosine monophosphate (cGMP)
pathway [16], and inhibition of hypercholesterolemia-induced
platelet aggregation [17]. In our previous report, we demonstrated
that total saponin from Korean Red Ginseng (KRG-TS) is a beneﬁcial
traditional Oriental medicine in platelet-mediated thrombotic dis-
ease via suppression of cyclooxygenase-1 (COX-1) and thromboxane
A2 (TXA2) synthase to inhibit production of thromboxane A2 [18]. In
addition, KRG-TS is involved in increase of cAMP levels and subse-
quent reduction of [Ca2þ] mobilization in thrombin-induced rat
platelet aggregation [19]. With regard to the effects of ginsenosides
on platelet aggregation, it is well known that ginsenoside Rg3
(G-Rg3) and its chemical derivatives (dihydroxyginsenoside
Rg3, ginsenoside Rp1) have antiplatelet effects by regulating
the aggregation-inhibiting molecule cAMP, and aggregation-
stimulating molecules [20,21]. In this study, we investigated the
novel effects of KRG-TS on the phosphorylation of VASP and
dephosphorylation of PI3K and Akt affecting on ﬁbrinogen and
ﬁbronectin binding to aIIb/b3. In addition, we found that ginseno-
side Ro (G-Ro), an oleanane type saponin, in KRG-TS has a potent
antiplatelet effect.
2. Materials and methods
KRG-TS was obtained from R&D Headquarter, Korea Ginseng
Corporation (Daejeon, Korea). Ginsenoside Ro was purchased from
Ambo Institute (Daejon, Korea). Thrombin was purchased from
Chrono-Log Corporation (Havertown, PA, USA). A CytoSelect 48-
well cell adhesion assay kit (Fibronectin-Coated, Colorimetric
Format) was purchased from Cell Biolabs (San Diego, CA, USA). A-
kinase inhibitor Rp-8-Br-cAMPS, G-kinase inhibitor Rp-8-Br-
cGMPS, A-kinase activator 8-(4-chlorophenylthio)-cAMP (pCPT-
cAMP), and G-kinase activator 8-Br-cGMP and 2-acetoxymethyl
(Fura 2-AM) were obtained from Sigma Chemical Corporation (St.
Louis, MO, USA). PI3K inhibitor wortmannin and cAMP enzyme
immunoassay (EIA) kit were obtained from Cayman Chemical (AnnArbor, MI, USA). Anti-phosphor-VASP (Ser157), anti-phosphor-VASP
(Ser239), anti-PI3K, anti-phosphor-PI3K (Tyr458), anti-Akt, anti-
phosphor-Akt (Ser473), and anti-rabbit immunoglobulin G (IgG)-
horseradish peroxidase conjugate (HRP), and lysis buffer were ob-
tained from Cell Signaling (Beverly, MA, USA). aIIb/b3 inhibitor
eptiﬁbatide, GR 144053, and anti-b-actin were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Polyvinylidene diﬂuoride
(PVDF) membrane was obtained from GE Healthcare (Piscataway,
NJ, USA). Enhanced chemiluminesence solution (ECL) was obtained
from GE Healthcare (Chalfont St, Giles, Buckinghamshire, UK).
Fibrinogen Alexa Fluor 488 conjugate was obtained from Invitrogen
Molecular Probes (Eugene, OR, USA).
2.1. Preparation of washed human platelets
Human platelet-rich plasma (PRP) anticoagulated with acid-
citrate-dextrose solution (0.8% citric acid, 2.2% sodium citrate,
2.45% glucose) was obtained from Korean Red Cross Blood Center
(Changwon, Korea). The PRP was centrifuged for 10 min at 125 g to
remove a few red blood cells, and was centrifuged for 10 min at
1,300 g to obtain the platelet pellets. The platelets werewashed two
times with washing buffer (138 mM NaCl, 2.7 mM KCl, 12 mM
NaHCO3, 0.36 mM NaH2PO4, 5.5 mM glucose, and 1 mM Na2EDTA,
pH 6.5). Thewashed platelets were then resuspended in suspension
buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO3, 0.36 mM
NaH2PO4, 0.49 mMMgCl2, 5.5 mM glucose, 0.25% gelatin, pH 6.9) to
a ﬁnal concentration of 5  108/mL. All of the aforementioned
procedures were carried out at 25C to avoid platelet aggregation
from any effect of low temperatures. The Korea National Institute
for the Bioethics Policy Public Institutional Review Board (Seoul,
Korea) approved these experiments (PIRB12-072).
2.2. Measurement of platelet aggregation
Washed human platelets (108/mL) were preincubated for 3 min
at 37C in the presence of 2mM exogenous CaCl2 with or without
substances, then stimulated with thrombin (0.05 U/mL) for 5 min.
Aggregation was monitored using an aggregometer (Chrono-Log
Corporation, Havertown, PA, USA) at a constant stirring speed of
1,000 rpm. Each aggregation rate was calculated as an increase in
light transmission. The suspension buffer was used as the reference
(transmission 0). KRG-TS was dissolved in the platelet suspension
buffer (pH 6.9).
2.3. Western blot for analysis of VASP-, PI3K-, and Akt-
phosphorylations
Washed human platelets (108/mL) were preincubated with or
without substances in the presence of 2mM CaCl2 for 3 min and
then stimulated with thrombin (0.05 U/mL) for 5 min at 37C in an
aggregometer at a constant stirring speed of 1,000 rpm. The re-
actionswere terminated by adding an equal volume (250 mL) of lysis
buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mMNa2EDTA, 1 mM EGTA,
1% Triton X-100, 2.5mM sodium pyrophosphate, 1 mM serine/
threonine phosphatase inhibitor b-glycerophosphate, 1 mM aden-
osine triphosphatase, alkaline and acid phosphatase, and protein
phosphotyrosine phosphatase inhibitor Na3VO4,1 mg/mL serine and
cysteine protease inhibitor leupeptin, and 1 mM serine protease
and acetylcholinesterase inhibitor phenylmethanesulfonyl ﬂuoride,
pH 7.5). Platelet lysates containing the same protein (15 mg) were
used for the analysis. Protein concentrationsweremeasured using a
bicinchoninic acid protein assay kit (Pierce Biotechnology, Rock-
ford, IL, USA). The effects of substances on VASP-, PI3K, and Akt-
phosphorylation were analyzed using Western blotting. A 6-8%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
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was used for protein transfer from the gel. The dilutions for anti-
phosphor-VASP (Ser157), anti-phosphor-VASP (Ser239), anti-PI3K,
anti-phosphor-PI3K (Tyr458), anti-Akt, anti-phosphor-Akt (Ser473),
and anti-rabbit IgG-HRP were 1:1,000, 1:1,000, 1:1,000, 1:1,000,
1:1,000, 1:1,000, and 1:10,000, respectively. The membranes were
visualized using ECL. The blots were analyzed using the Quantity
One, version 4.5 (BioRad, Hercules, CA, USA).
2.4. Determination of ﬁbrinogen binding to aIIb/b3
Washed human platelets (108/mL) were preincubated for 3 min
at 37C with or without substances in the presence of 2mM CaCl2
and then stimulated with thrombin (0.05 U/mL) in the presence of
Alexa Flour 488-human ﬁbrinogen (30 mg/mL) for 5 min at 37C.
The reactionwas stopped by the addition of 0.5% paraformaldehyde
in phosphate buffered saline, and the samples were placed in the
dark. Alexa Fluor 488-ﬁbrinogen binding to platelets was deter-
mined using ﬂowcytometry (BD Biosciences, San Jose, CA, USA) and
ﬁbrinogen binding to aIIb/b3 was analyzed using cellQuest software
(BD Biosciences, San Jose, CA, USA).
2.5. Determination of ﬁbronectin adhesion
Adhesion assay was performed with the CytoSelect 48-well cell
adhesion assay kit (Cell Biolabs, San Diego, CA, USA). The plates
were coated with ﬁbronectin or bovine serum albumin (BSA) as a
negative control. Washed human platelets (108/mL) were incubated
for 60 min at 37C in the presence of thrombin (0.05 U/mL) with or
without various concentrations of KRG-TS. After ﬁve times washing
with phosphate buffered saline, cell stain solution was added and
the plates were incubated at room temperature for 10 min. After
washing ﬁve times, extraction solution was added and the plates
were incubated for 10 min. Each sample was transferred to a 96-
well microtiter plate and measured with Synergy HT Multi-Model
Microplate Reader (BioTek Instruments, Winooski, VT, USA) at an
optical density of 560 nm.
2.6. Assay of platelet-mediated ﬁbrin clot retraction
Human PRP 250 mL were transferred into a polyethylene tube to
avoid clot adherence, then were preincubated with or without
KRG-TS (150 mg/mL) for 10 min at 37C, and subsequently stimu-
latedwith thrombin (0.05 U/mL) for 5 min at 37C. Pictures of ﬁbrin
clot were taken at 5 min using a digital camera, and its quantiﬁ-
cationwas carried out bymeasurement of clot area using the Image
J Software (version 1.46, National Institutes of Health, Bethesda,
MD, USA). Percentage of clot retraction was calculated as follows:
Retraction (%) by thrombin ¼ (basal area e thrombin area) / basal
area  100.
2.7. Determination of cytosolic-free Ca2þ ([Ca2þ]i)
Human PRP was incubated with 5mM Fura 2-AM at 37C for
60 min. Because Fura 2-AM is light sensitive, the tube containing
the PRP was covered with aluminum foil during loading. The Fura
2-loaded washed platelets were prepared using the procedure
described previously and platelets (108/mL) were preincubated for
3 min at 37C with or without G-Ro (200 mM) in the presence of
2mM CaCl2, then stimulated with thrombin (0.05 U/mL) for 5 min
for evaluation of [Ca2þ]i. Fura 2 ﬂuorescence was measured with a
spectroﬂuorometer (SFM 25, BioTeck Instrument, Milan, Italy) withan excitationwavelength that was changed every 0.5 s from340 nm
to 380 nm; the emission wavelength was set at 510 nm. The [Ca2þ]i
values were calculated using the method of Grynkiewicz et al [22].
2.8. Measurement of cAMP
Washed human platelets (108/mL) were preincubated for 3 min
at 37C with or without G-Ro (200 mM) in the presence of 2 mM
CaCl2, then stimulated with thrombin (0.05 U/mL) for 5 min for
platelet aggregation. The aggregation was terminated by the
addition of 80% ice-cold ethanol. cAMPwasmeasuredwith Synergy
HT Multi-Model Microplate Reader (BioTek Instruments) using a
cAMP EIA kit.
2.9. Statistical analyses
The experimental results are expressed as the mean  standard
deviation accompanied by the number of observations. Data were
assessed by analysis of variance (ANOVA). If this analysis indicated
signiﬁcant differences among the group means, then each group
was compared by the Newman-Keuls method. Statistical analysis
was performed according to the SPSS 21.0.0.0 (SPSS Inc., Chicago, IL,
USA). A p value < 0.05 was considered to be statistically signiﬁcant.
3. Results
3.1. Effects of KRG-TS on thrombin-induced human platelet
aggregation
The concentration of thrombin-induced maximal human
platelet aggregationwasw0.05 U/mL (Fig. 1A). Therefore, thrombin
(0.05 U/mL) was used as the human platelet agonist in this study. In
intact platelets, the light transmission in response to various con-
centrations of KRG-TS (25 mg/mL, 50 mg/mL, 100 mg/mL, 150 mg/mL)
was 1.3  0.6% (at 25 mg/mL of KRG-TS), 1.3  0.6% (at 50 mg/mL of
KRG-TS), 1.3  0.6% (at 100 mg/mL of KRG-TS), and 1.3  0.6% (at
150 mg/mL of KRG-TS), respectively, which were not signiﬁcantly
different from that (1.0  0.0%) in resting platelets without KRG-TS
(Fig. 1B). When washed human platelets (108/mL) were activated
with thrombin, the aggregation rate was increased up to
87.8  5.7%. However, various concentrations of KRG-TS (25e
150 mg/mL) signiﬁcantly reduced thrombin-stimulated platelet
aggregation in a dose-dependent manner (Figs. 1B, C), and the half-
maximal inhibitory concentration (IC50) was w45 mg/mL (Fig. 1D).
This IC50 is low as compared with that (81.1 mg/mL) from rat
platelets [19]. In addition, 150 mg/mL of KRG-TS inhibited to 95.9%
thrombineinduced human platelet aggregation (87.8  5.7%).
3.2. Effects of KRG-TS on VASP phosphorylation
Because 150 mg/mL of KRG-TS (Fig. 1B) signiﬁcantly inhibited
thrombin-induced platelet aggregation, we used 150 mg/mL of KRG-
TS to evaluate its effect on various signaling molecules. KRG-TS
activated the phosphorylation of VASP (Ser157), an A-kinase sub-
strate (Fig. 2A, lane 3). Next we investigated whether VASP (Ser157)
phosphorylation by KRG-TS is dependent on cAMP/A-kinase
pathway. A-kinase inhibitor Rp-8-Br-cAMPS (Fig. 2A, lane 4)
potently decreased KRG-TS (150 mg/mL)-induced VASP (Ser157)
phosphorylation. A-kinase activator pCPT-cAMP stimulated also
VASP (Ser157) phosphorylation, indicating dependence on cAMP
(Fig. 2A, lane 5). Although G-kinase activator 8-Br-cGMP stimulated
VASP (Ser239) phosphorylation, indicating dependence on cGMP
(Fig. 2B, lane 5), KRG-TS (150 mg/mL) did not increase the VASP
(Ser239) phosphorylation (Fig. 2B, lane 3).
Fig. 1. Effects of total saponin Korean Red Ginseng (KRG-TS) on thrombin-induced human platelet aggregation. (A) The concentration threshold of thrombin on human platelet
aggregation. (B) Effects of KRG-TS on thrombin-induced human platelet aggregation. (C) The inhibitory effects of KRG-TS on thrombin-induced human platelet aggregation. (D) The
half maximal inhibitory concentration (IC50) value of KRG-TS in thrombin-stimulated human platelet aggregation. Measurement of platelet aggregation was carried out as described
in the Materials and methods section. The rate of inhibition by KRG-TS was recorded as the percentage of the thrombin induced aggregation rate. The IC50 value of KRG-TS was
calculated according to the four-parameter log ﬁt method. The data are expressed as the mean  standard deviation (n ¼ 4). *p < 0.05 versus the thrombin-stimulated platelets.
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Next, we investigated whether the VASP (Ser157) phosphoryla-
tion by KRG-TS was involved in inhibition of ﬁbrinogen binding to
aIIb/b3. As shown in Fig. 3A, thrombin activated the ﬁbrinogen
binding to aIIb/b3 (Figs. 3A, B), and increased to 92.1  2.1%
ﬁbrinogen binding to aIIb/b3 (Figs. 3A and B) from that (1.7  0.2%)
of intact platelets, control (Table 1). However, KRG-TS dose (25e
150 mg/mL) dependently inhibited thrombin-activated ﬁbrinogen
binding to aIIb/b3 (Figs. 3A-cef, 3B), and KRG-TS (150 mg/mL)
inhibited to 91.6% ﬁbrinogen binding as compared with that
(92.1  2.1%) by thrombin (Table 1). Although it is known that
cAMP- and cGMP-increasing compounds are involved in inhibition
of aIIb/b3 via cAMP/A-kinase, and cGMP/G-kinase pathway [23,24],
in this study, because KRG-TS did not phosphorylated VASP (Ser239)
(Fig. 2B), we investigated whether the inhibition of ﬁbrinogen
binding to aIIb/b3 by KRG-TS resulted from cAMP/A-kinase
pathway. A-kinase activator pCPT-cAMP inhibited thrombin-
induced ﬁbrinogen binding to aIIb/b3 (Figs. 4Aeb, B), which in-
dicates that cAMP/A-kinase pathway involves inhibition of ﬁbrin-
ogen binding to aIIb/b3 in thrombin-induced platelet aggregation.
KRG-TS (150 mg/mL)-inhibited ﬁbrinogen binding to aIIb/b3 was
elevated by A-kinase inhibitor Rp-8-Br-cAMPS (Figs. 4Aea, B), and
its stimulatory degree was 350% as compared with that (7.7%) by
both KRG-TS and thrombin (Table 1).
3.4. Effects of KRG-TS on PI3K/Akt phosphorylation
As apposed to the phosphorylated VASP, PI3K/Akt phosphoryla-
tion stimulates aIIb/b3 activation and ﬁbrinogen binding [25,26].
Thus,we investigated the effect of KRG-TS onphosphorylation of PI3K
and its downstream molecule Akt. Thrombin potently phosphory-
latedPI3K (Fig. 5, lane 2) as comparedwith that (Fig. 5, lane1)of intactplatelets. However, KRG-TS (Fig. 5, lanes 3 and 4) inhibited thrombin-
induced PI3K phosphorylation. Moreover, PI3K inhibitor wortman-
nin, negative control, suppressed thrombin-induced PI3K phosphor-
ylation (Fig. 5, lane 5). Thrombin elevated the phosphorylationof PI3K
target molecule Akt (Fig. 6, lane 2). However, KRG-TS inhibited
thrombin-induced Akt phosphorylation (Fig. 6, lanes 3 and 4).
3.5. Effects of KRG-TS on adhesion to ﬁbronectin
Integrin aIIbb3 also served as a ﬁbronectin receptor on platelets
and occupancy of this receptor is essential for platelet adhesion.
Therefore, we determined whether KRG-TS interferes with ﬁbro-
nectin binding to aIIbb3. As shown in Fig. 7, thrombin did not
adhere platelets to bovine serum albumin (BSA), negative control,
but thrombin potently adhered platelets to ﬁbronectin. These mean
that thrombin induced ﬁbronectin adhesion to aIIb/b3 of platelets,
but not BSA (Fig. 7A). KRG-TS (25e150 mg/mL) dose dependently
decreased thrombin-induced ﬁbronectin adhesion, and aIIbb3 in-
hibitors (eptiﬁbatide and GR 144053) also inhibited thrombin-
induced ﬁbronectin adhesion. Next, we investigated whether
ﬁbronectin inhibition by KRG-TS was resulted from cAMP/A-kinase
activation. A-kinase inhibitor Rp-8-Br-cAMPS increased KRG-TS-
decreased ﬁbronectin binding to aIIbb3 (Fig. 7B). Moreover, A-ki-
nase activator pCPT-cAMP inhibited thrombin-induced ﬁbronectin
binding to aIIb/b3 (Fig. 7B), which means that cAMP/A-kinase
activation is involved in inhibition of ﬁbronectin adhesion.
3.6. Effects of KRG-TS on retraction of ﬁbrin clot
Activation of aIIbb3 (inside-out signaling) by platelet agonists
induces ﬁbrinogen binding to aIIbb3, and leads to outside-in aIIbb3
signaling, containing clot retraction, platelet spreading, stable
adhesion, granule secretion, protein phosphorylation, platelet
Fig. 2. Effects of total saponin Korean Red Ginseng (KRG-TS) on vasodilator-stimulated
phosphoprotein (VASP) phosphorylation. (A) Effect of KRG-TS on VASP (Ser157) phos-
phorylation. Lane 1, Intact platelets (base); Lane 2, Thrombin (0.05 U/mL); Lane 3,
Thrombin (0.05 U/mL) þ KRG-TS (150 mg/mL); Lane 4, Thrombin (0.05 U/mL) þ KRG-TS
(150 mg/mL) þ Rp-8-Br-cAMPS (250 mM); and Lane 5, Thrombin (0.05 U/mL) þ pCPT-
cAMP (1mM). (B) Effect of KRG-TS on VASP (Ser239) phosphorylation. Lane 1, Intact
platelets (base); Lane 2, Thrombin (0.05 U/mL); Lane 3, Thrombin (0.05 U/mL)þ KRG-TS
(150 mg/mL); Lane 4, Thrombin (0.05 U/mL) þ KRG-TS (150 mg/mL) þ Rp-8-Br-cGMPS
(250mM); and Lane 5, Thrombin (0.05 U/mL)þ 8-Br-cGMP (1mM).Western blottingwas
performed as described in theMaterials and methods section. The data are expressed as
the mean  standard deviation (n ¼ 4). *p < 0.05 versus the thrombin-stimulated
platelets. ** p < 0.05 versus the thrombin-stimulated platelets in the presence of
KRG-TS (150 mg/mL). cAMP ¼ cyclic adenosine monophosphate; cGMP ¼ cyclic aden-
osine monophosphate; pCPT-cAMP ¼ 8-(4-chlorophenylthio)-cAMP
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Here, we investigated the effect of KRG-TS on retraction of
thrombin-induced ﬁbrin clot, an index of outside-in aIIbb3
signaling. Photographs in Fig. 8A show that thrombin stimulated
the formation of ﬁbrin clot, and the retraction of ﬁbrin clot. The
degree of retractionwas determined from quantitation of ﬁbrin clot
area by Image J Software (version 1.46, National Institutes of Health,
Bethesda, MD, USA). As shown in Fig. 8B, thrombin potently
retracted ﬁbrin clot, and increased to 60% the rate of clot retraction
as compared with that without thrombin intact (55  1.3 mm2).
However, KRG-TS suppressed thrombin-retracted ﬁbrin clot, and its
inhibitory degree was 82% as compared with that by thrombin
(22  1.1 mm2; Fig. 8B).3.7. Effects of G-Ro on platelet aggregation, [Ca2þ]i mobilization,
and cAMP production
In our previous report [30], we showed that protopanaxadiol
type saponins (G-Ra1, G-Rb1, G-Rb2, G-Rb3, G-Rc, G-Rd, G-Rh2),
and protopanaxatriol type saponins (G-Re, G-Rf, G-Rg1, G-Rg2, G-
Rh1) have no antiplatelet effect on thrombin-induced human
platelet aggregation. In this study, however, we found that G-Ro, an
oleanane type saponin, has a potent antiplatelet effect. When hu-
man platelets (108/mL) were stimulated by thrombin (0.05 U/mL),
platelet aggregation was potently increased (Table 2). However, G-
Ro inhibited thrombin-induced platelet aggregation, its inhibitory
degree was 52.0% as compared with that by thrombin (86.7  1.5%;
Table 2). G-Ro increased to 89.1% the production of Ca2þ-antago-
nistic cAMP, and decreased to 77.3% the level of aggregating-
molecule [Ca2þ]i in thrombin-induced platelet aggregation
(Table 2).
4. Discussion
Of several aggregation inhibiting molecules, cAMP and cGMP
are essential for inhibition of platelet aggregation. These cyclic
nucleotides generate various biological functions (i.e., VASP phos-
phorylation, IP3R phosphorylation) via cAMP/A-kinase- or cGMP/G-
kinase-pathway.
A downstream pathway of both cAMP/A-kinase and cGMP/G-
kinase is involved in VASP phosphorylation to inhibit aIIb/b3 ac-
tivity. Ser157 at 50 kDa of VASP [VASP (Ser157)] is phosphorylated
by the cAMP/A-kinase pathway, whereas Ser239 at 50 kDa of VASP
[VASP (Ser239)] is phosphorylated by the cGMP/G-kinase pathway
[24,31]. KRG-TS markedly phosphorylated A-kinase substrate VASP
(Ser157), but did not phosphorylate G-kinase substrate VASP
(Ser239) in thrombin-induced platelet aggregation. These results
suggest that the VASP (Ser157) phosphorylation by KRG-TS is
possibly achieved by stimulating cAMP/A-kinase pathway, as evi-
denced by the fact that KRG-TS elevated cAMP only of cAMP and
cGMP in thrombin-induced platelet aggregation [19]. Otherwise,
A-kinase inhibitor Rp-8-Br-cAMPS would not decrease KRG-TS-
elevated VASP (Ser157) phosphorylation. In addition, A-kinase in-
hibitor Rp-8-Br-cAMPS increased KRG-TS-inhibited ﬁbrinogen
binding to aIIb/b3. In this study, we have established that the
inhibitory effect by KRG-TS on thrombin-induced aIIb/b3 activa-
tion is due to cAMP/A-kinase-dependent VASP (Ser157) phos-
phorylation, as evidenced by the fact that cAMP/A-kinase pathway
involves suppression of aIIb/b3 activation [3,4,32]. cAMP-elevating
agents (i.e., cilostamide, cilostazole, and forskolin) are known to
inhibit PI3K- and Akt-phosphorylation in thrombin-induced
platelet aggregation [33]. Therefore, KRG-TS that increases cAMP
level [19] may be involved in inhibition of PI3K/Akt phosphory-
lation, and subsequently could participate in suppression of aIIb/b3
activation.
Platelet adhesion is the ﬁrst step in the hemostatic response and
various adhesive proteins such as von Willebrand factor, collagen,
and ﬁbronectin canmediate as substrates for platelet adhesion [34].
Fibronectin adhesion is mediated by both a5b1 and aIIb/b3, and
subsequently is involved in platelet spreading, plug formation, and
a series of events of outside-in signaling [34,35]. We clearly showed
that KRG-TS strongly attenuated ﬁbronectin binding to aIIb/b3 in a
cAMP/A-kinase-dependent manner, as veriﬁed that A-kinase in-
hibitor Rp-8-Br-cAMPS increased KRG-TS-reduced ﬁbronectin
binding in thrombin-induced platelet aggregation.
Fibrinogen binding to aIIb/b3 is involved in ﬁbrin clot retraction,
which is an index of thrombus intensiﬁcation [27], and is known to
be involved in promotion of atheroprogression [36,37]. If so, inhi-
bition of ﬁbrinogen-, ﬁbronectin-binding and clot retraction is a
Fig. 3. Effects of total saponin Korean Red Ginseng (KRG-TS) on thrombin-induced ﬁbrinogen binding. (A) The ﬂow cytometry histograms on ﬁbrinogen binding: a, intact platelets
(base); b, thrombin (0.05 U/mL); c, thrombin (0.05 U/mL) þ KRG-TS (25 mg/mL); d, thrombin (0.05 U/mL) þ KRG-TS (50 mg/mL); e, thrombin (0.05 U/mL) þ KRG-TS (100 mg/mL); and
f, thrombin (0.05 U/mL) þ KRG-TS (150 mg/mL). (B) Effects of KRG-TS on thrombin-induced ﬁbrinogen binding (%). Determination of ﬁbrinogen binding to aIIb/b3 was carried out as
described in the Materials and methods section. The data are expressed as the mean  standard deviation (n ¼ 4). * p < 0.05 versus the thrombin-stimulated platelets.
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thrombotic disease.
Platelet aggregation is generated at the site of vascular wall
injury, and is involved in the formation of thrombus. During the
formation of thrombus, platelets release cell growth proteins such
as platelet-derived growth factor (PDGF), and vascular endothelial
growth factor (VEGF) in their a-granule [38,39]. It is well estab-
lished that PDGF and VEGF induce the proliferation of ﬁbroblast,vascular smooth cells, and epithelial cells, and subsequently
enhance the rate of atherosclerosis lesion progression [40e44]. The
progression of atherosclerosis is strongly induced by inﬂammatory
cells such as monocyte/macrophage, and neutrophil [45]. Although
KRG-TS has antiplatelet effects, if KRG-TS does not inhibit inﬂam-
mation by leukocytes, the progression of atherosclerosis lesion
would be generated at the site of vascular wall injury, and a ques-
tion regarding antiplatelet effects of KRG-TS might be raised. Byeon
Table 1
Effects of Rp-8-Br-cAMPS on ﬁbrinogen binding1)
Fibrinogen Binding (%) D(%)
Intact platelets 1.7  0.2 d
Thrombin (0.05 U/mL) 92.1  2.1 d
KRG-TS (150 mg/mL) 7.7  0.2 91.6 2)
þ Thrombin (0.05 U/mL)
KRG-TS (150 mg/mL) 34.8  0.4 þ350 3)
þ Thrombin (0.05 U/mL)
þ Rp-8-Br-cAMPS (250mM)
cAMP, cyclic adenosine monophosphate; KRG-TS, total saponin Korean Red Ginseng
1) Data from Figs. 3B, 4B
2) D (%) ¼ [(KRG-TS þ Thrombin) e Thrombin]/Thrombin  100
3) D (%) ¼ [(KRG-TS þ Thrombin þ Rp-8-Br-cAMPS) e (KRG-TS þ Thrombin)] /
(KRG-TS þ Thrombin)]  100
Fig. 5. Effects of total saponin Korean Red Ginseng (KRG-TS) on PI3K phosphorylation.
Lane 1, Intact platelets (base). Lane 2, Thrombin (0.05 U/mL). Lane 3, Thrombin (0.05 U/
mL) þ KRG-TS (100 mg/mL). Lane 4, Thrombin (0.05 U/mL) þ KRG-TS (150 mg/mL). Lane
5, Thrombin (0.05 U/mL) þ wortmannin (10mM). Western blotting was performed as
described in the Materials and methods section. The data are expressed as the
mean  standard deviation (n ¼ 4). * p < 0.05 versus the thrombin-stimulated
platelets.
J Ginseng Res 2016;40:76e8582et al. [46] reported that saponin fraction inhibits lipopolysaccharide
(LPS)-induced inﬂammation, and it is well reviewed that ginseno-
sides have anti-inﬂammatory effects by inhibiting the production
of various pro-inﬂammatory mediators [i.e., prostaglandin E2, nitric
oxide (NO)] [47]. Recently, it was reported that Korean Red Ginseng
saponin fraction downregulates LPS-induced proinﬂammatory
mediators (i.e., NO, interleukin-1b) [48]. In addition, Yang et al. [49]
clariﬁed that protopanaxadiol saponin fraction inhibits inﬂamma-
tory actions via suppression of p38-, JNK2-, and TANK [tumor ne-
crosis factor receptor-associated factor (TRAF) family member-
associated nuclear factor-k-B activator]-binding kinase-1-linked
pathway and their corresponding transcription factors (i.e., acti-
vation transcription factor 2, interferon regulatory transcription
factor 3). Considering these previous reports [46e49], it is thought
that KRG-TS may have antithrombotic, and antiatherosclerotic ef-
fects without generation of inﬂammation and progression of
atherosclerotic lesion at the site of vascular wall injury. Therefore,
KRG-TS is highlighted as a nontoxic antiplatelet compound, andFig. 4. Effects of total saponin Korean Red Ginseng (KRG-TS) on thrombin-induced ﬁbrinogen
histograms on ﬁbrinogen binding: a, thrombin (0.05 U/mL) þ KRG-TS (150 mg/mL) þ Rp-8-Br
TS on thrombin-induced ﬁbrinogen binding (%). Determination of ﬁbrinogen binding to aI
expressed as the mean  standard deviation (n ¼ 4). * p < 0.05 versus the thrombin-stimu
KRG-TS (150 mg/mL). cAMP ¼ cyclic adenosine monophosphate; pCPT-cAMP ¼ 8-(4-chlorocould be clinically applied to the prevention of platelet-mediated
thrombosis. This is supported from reports that Korean Red
Ginseng has protective effects on rat carotid artery thrombosis
in vivo [50], and both ginseng and ginsenoside are beneﬁcial can-
didates for prevention of cardiovascular disease [51].binding in the presence of A-kinase inhibitor (Rp-8-Br-cAMPS). (A) The ﬂow cytometry
-cAMPS (250mM) and b, thrombin (0.05 U/mL) þ pCPT-cAMP (1mM). (B) Effects of KRG-
Ib/b3 was carried out as described in the Materials and methods section. The data are
lated platelets. ** p < 0.05 versus the thrombin-stimulated platelets in the presence of
phenylthio)-cAMP
Fig. 6. Effects of total saponin Korean Red Ginseng (KRG-TS) on Akt phosphorylation.
Lane 1, Intact platelets (base). Lane 2, Thrombin (0.05 U/mL). Lane 3, Thrombin (0.05 U/
mL) þ KRG-TS (100 mg/mL). Lane 4, Thrombin (0.05 U/mL) þ KRG-TS (150 mg/mL).
Western blotting was performed as described in theMaterials and methods section. The
data are expressed as the mean  standard deviation (n ¼ 4). * p < 0.05 versus the
thrombin-stimulated platelets.
Fig. 7. Effects of total saponin Korean Red Ginseng (KRG-TS) on thrombin-induced
ﬁbronectin adhesion. (A) Inhibitory effects of KRG-TS on ﬁbronectin adhesion. (B) Ef-
fects of KRG-TS on thrombin-induced ﬁbronectin adhesion in the presence of A-kinase
inhibitor (Rp-8-Br-cAMPS). Measurement of ﬁbronectin adhesion was carried out as
described in theMaterials and methods section. BSA ¼ bovine serum albumin (negative
control). The data are expressed as the mean  standard deviation (n ¼ 4). * p < 0.05
versus the thrombin-stimulated platelets. ** p < 0.05 versus the thrombin-stimulated
platelets in the presence of KRG-TS (150 mg/mL).
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water extract, tea, drink) is known to inhibit platelet aggregation,
blood coagulation, and hyperlipidemia such as indexes of throm-
botic diseases and atherosclerosis, and their effects were also well
sustained in the patients who have obesity, hyperlipidemia, and
hypertension [52,53].
Hwang et al. [17] reported that dietary water-extract of Korean
Red Ginseng (KRG-WE) inhibited collagen-induced rabbit platelet
aggregation under hypercholesterolemia causing atherosclerosis
such as cardiovascular disease, and KRG-WE had a strong anti-
platelet effects as compared with those caused by lovastatin, an
anticholesterolemic drug. Oral administration (250e500 mg/kg-
body weight-rat) of KRG-WE signiﬁcantly inhibited agonists (i.e.,
ADP, collagen)-induced platelet aggregation, and KRG-WE (300 mg/
mL, 500 mg/mL) inhibited agonists (i.e., ADP, collagen, etc.)-induced
washed rabbit platelet aggregation in vitro [49]. If these are phys-
iological concentrations (300 mg/mL, 500 mg/mL) of KRG-WE to
inhibit rat and rabbit platelet aggregation in in vitro and in vivo,
because it is thought that we used KRG-TS (150 mg/mL) is low
concentration as compared with that of KRG-WE in vitro (300 mg/
mL, 500 mg/mL), in this study, it is unknown whether in vitro KRG-
TS (150 mg/mL)-mediated antiplatelet effects are also expressed
in vivo. These should be studied in the future.
With regard to the G-Ro, Sanada et al. [54] reported that G-Ro is
contained in Panax ginseng, Choi [55] reviewed that G-Ro (0.045 w/
w %), and G-Rg3 (20S, 0.006 w/w %) and G-Rg3 (20R, 0.014 w/w %)
are contained in Panax ginseng, but not in Panax notoginseng (Sanchi
ginseng), and Panax quinquefolius (American ginseng). It is known
that G-Ro (1mM) inhibited arachidonic acid-induced platelet ag-
gregation and ﬁbrin formation in vitro [56], and G-Ro (10e50mg/kg
body weight-rat) administration activated ﬁbrinolysis, indicating
the inhibition of ﬁbrin thrombi [57]. Accordingly, when
antiplatelet-mediated 200mM (about 191.4 mg/kg) of G-Ro (MW.
957.1) is administered to animals, it is unknownwhether thrombin-
induced platelet aggregation would also be inhibited in vivo.
However, considering thrombin is involved in platelet aggregation
and ﬁbrin formation, it is thought that G-Ro 200mM (191.4 mg/kg)would be involved in inhibition of platelet aggregation and ﬁbrin
formation. Currently, G-Ro is known to have anti-inﬂammatory
effects [58]. If so, it is thought that G-Ro may also have a protec-
tive effect on thrombosis through inhibition of platelet aggregation
and inﬂammation.
It is known that G-Ro does not inhibit collagen-induced [Ca2þ]i
mobilization [59], however, in this study, we conﬁrmed that G-Ro
inhibits [Ca2þ]i mobilization by increasing Ca2þ-antagonistic cAMP
in thrombin-induced platelet aggregation. Therefore, it is thought
that G-Ro-elevated cAMP also may be involved in VASP (Ser157)
phosphorylation in the same manner that KRG-TS activated cAMP-
dependent VASP (Ser157) phosphorylation.
G-Rg3 (20S, 20R) is known to have antiplatelet effects by
regulating various aggregating molecules [20,21]. Recently, we also
reported that only G-Rg3 (20S, 20R) of protopanaxadiol saponin
have inhibitory effects on thrombin-induced platelet aggregation
[30]. Antiplatelet effects of G-Ro and G-Rg3 indicated that Panax
ginsengwould have an excellent antithrombotic effect by inhibiting
platelet aggregation than that by any ginsengs, and G-Ro and G-Rg3
(20S, 20R) are major compounds in KRG-TS only of Panax ginseng.
Table 2
Effects of G-Ro on platelet aggregation, [Ca2þ]i mobilization, and cyclic adenosine monophosphate production in thrombin-induced human platelet activation
Aggregation (%) D (%) cAMP
(pmol/108 platelets)
D (%) Ca2þ (nM) D (%)
Basal (control) - 4.8  0.3 d 102.4  0.5 d
Thrombin (0.05 U/mL) 86.7  1.5 d 4.6  0.1 0 655.7  38.7 þ540.3 2)
G-Ro (200 mM) þ Thrombin (0.05 U/mL) 41.7  2.5* 52.0 1) 8.7  1.0* þ89.1 1) 149.0  3.8* 77.3 1)
The data are expressed as the mean  standard deviation (n ¼ 4)
* p < 0.05 versus the thrombin-stimulated platelets
cAMP ¼ cyclic adenosine monophosphate
1) D (%) ¼ [Thrombin e (G-Ro þ Thrombin) / Thrombin  100
2) (Basal e Thrombin)/Basal  100
Fig. 8. Effects of total saponin Korean Red Ginseng (KRG-TS) on ﬁbrin clot retraction.
(A) Photographs of ﬁbrin clot. (B) Effects of KRG-TS on thrombin-retracted ﬁbrin clot.
Quantiﬁcation of ﬁbrin clot retraction was performed as described in the Materials and
methods section. (1) ¼ (base e thrombin)/base  100, 2) ¼ [base e (thrombin þ KRG-
TS)]/base  100, 3) ¼ [thrombin e (thrombin þ KRG-TS)]/thrombin  100. The data are
expressed as the mean  standard deviation (n ¼ 4).
* p < 0.05 versus the thrombin-stimulated platelets.
J Ginseng Res 2016;40:76e8584In conclusion, the most important result of this study is that
KRG-TS signiﬁcantly inhibits binding of adhesive proteins (i.e.,
ﬁbrinogen, ﬁbronectin) to aIIb/b3 by activating the phosphorylation
of VASP (Ser157) and dephosphorylation of PI3K and Akt, which
contribute to inhibition of thrombotic formation. Therefore, we
suggest that KRG-TS may be a physiologically effective negative
regulator in thrombosis, atherosclerosis, and myocardial infarction
via inhibition of platelet aggregation.Conﬂicts of interest
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